Moody's Investors Service ("Moody's") assigned an A3 rating to the new CHF-denominated senior unsecured notes offering by Thermo Fisher Scientific Inc. ("Thermo Fisher"). There are no changes to Thermo Fisher's existing ratings including the A3 senior unsecured long-term ratings and the Prime-2 seni...
A director at Thermo Fisher Scientific Inc sold 5,547 shares at 550.620USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Moody's Investors Service ("Moody's") assigned an A3 rating to the new senior unsecured notes offering by Thermo Fisher Scientific Inc. ("Thermo Fisher"). There are no changes to Thermo Fisher's existing ratings including the A3 senior unsecured long-term ratings and the senior unsecured commercial ...
Moody's Investors Service ("Moody's") assigned an A3 rating to the new senior unsecured notes offering by Thermo Fisher Scientific Inc. ("Thermo Fisher"). There are no changes to Thermo Fisher's existing ratings including the A3 senior unsecured long-term rating and the Prime-2 short-term rating. Th...
We have calculated the significant supply about to enter the biologics manufacturing space & analysed demand growth. Whilst the market assumes an improvement in utilisation from 2024, we forecast there will be significant overcapacity in the coming years resulting in even lower utilisation at an industry level. Our detailed bottom-up analysis shows that total mammalian cell supply is set to grow by 11% p.a. 2023-26 but demand is set to grow just 8% p.a. over the same period. However, much more c...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Following recent news from Catalent & Polypeptide, our deep dive on the state of the CDMO and Bioprocessing Supplier industry shows that inventories have soared as sales were pulled forward & slow biotech funding will likely diminish demand for 1H23. At the same time, supply has expanded and energy, input & labour costs are all going up. We believe that book-to-bill ratios will likely stay below 1.0 until at least Q123 for many co’s. As a result, margins will come under pressure from softer pric...
Moody's Investors Service ("Moody's") assigned an A3 rating to the new senior unsecured notes offering by Thermo Fisher Scientific Inc. ("Thermo Fisher"). There are no changes to Thermo Fisher's existing ratings including the A3 senior unsecured long-term rating and the Prime-2 short-term rating. Th...
Moody's Investors Service ("Moody's") assigned an A3 rating to the new yen-denominated senior unsecured notes offering of Thermo Fisher Scientific Inc. ("Thermo Fisher"). There are no changes to Thermo Fisher's existing ratings including the A3 senior unsecured long-term rating and the Prime-2 short...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.